- CONDITION CENTERS
Sagent Pharmaceuticals Inc (Schaumburg, IL) recently launched CefAZOLIN for Injection, USP?an essential antibiotic used to treat serious infections. The product is the generic equivalent to GlaxoSmithKline?s Ancef. CefAZOLIN for Injection, USP, is indicated for serious infections such as those of the respiratory, biliary and urinary tracts, skin and skin structure infections, bone and joint infections, and other infections caused by various strains of streptococci. Prophylactic CefAZOLIN Injection, USP, preoperative, intraoperative, and postoperative administration can be effective in reducing the incidence of certain surgical infections. The product is available in 1-g single-dose vials and 10-g pharmacy bulk-package vials. For more information, call 866-625-1618, or visit www.SagentPharma.com.
Cephalon Inc (Frazer, PA) recently received FDA approval for Treanda for Injection. The product is an alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. Treanda for Injection is intended for administration as an intravenous infusion over 30 minutes. The recommend dose is 100 mg/ m2 administered intravenously on days 1 and 2 of a 28-day cycle, up to 6 cycles. The product is supplied in individual cartons of 20-mL amber single-use vials containing 100 mg of bendamustine hydrochloride as a white to offwhite lyophilized powder. Treanda for Injection has been granted orphan drug status by the FDA for the treatment of CLL. The orphan drug designation will provide marketing exclusivity in this indication until March 2015. For more information, visit www.cephalon.com, or call 800-896-5855.
Merck & Co Inc (Whitehouse Station, NJ) recently received FDA approval for Emend for Injection, a new intravenous (IV) therapy for the prevention of chemotherapy- induced nausea and vomiting. The product is an IV prodrug of the oral formulation of Emend (aprepitant). When Emend for Injection is administered, fosaprepitant is rapidly converted in the body to aprepitant. Emend for Injection is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic and highly emetogenic cancer chemotherapy, including highdose cisplatin. Emend for Injection (115 mg) provides a new option for patients receiving an antiemetic on day 1 of their chemotherapy. The product may be substituted for the 125-mg oral capsule of Emend on day 1 and is administered 30 minutes prior to the initiation of chemotherapy over a 15-minute period. The 3-day antiemetic regimen includes Emend for Injection (115 mg) or Emend (125 mg orally) on day 1; Emend (80 mg orally) on days 2 and 3; in addition to a corticosteroid and a 5-HT3 antagonist. The product is supplied as one 115-mg single dose per 10-mL glass vial. For more information, call 800-NSC-MERCK (800-672-6372), or visit www.emendforinjection.com.
Sculptor Developmental Technologies Inc?s (Canonsburg, PA) VeriScan is designed to prevent medication errors at the patient bedside at the time the medication is being administered. The system provides nurses with medications sorted according to those due now, PRN orders, and all orders. New orders, changes to orders, and discontinued orders are delivered to the personal digital assistant (PDA) in real time. In addition to supporting barcode scanning, VeriScan is designed to support radio-frequency identification (RFID) technology. User sign-on and patient identification (ID) are 2 key areas to use RFID. Instead of scanning the bar code on the user ID or patient wristband, the PDA is placed in the proximity (within 3 in) of the user ID or patient wristband. With VeriScan, the process of charting medications to the order-entry system can take place at the same time the medication is given at the patient bedside. Eliminating delays in charting medications also provides a positive impact on patient safety, because all clinicians who use the order-entry system will have up-to-the-minute status on the administration of each patient?s medications. For more information, visit www.BedSideSafety.com
bioM?rieux Inc (Durham, NC) recently received 510(k) clearance from the FDA to market VIDAS NT-proBNP?a test that helps the diagnosis of heart failure. VIDAS NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a quantitative marker of heart stress with the potential to detect all stages of heart failure, even the early stages, which can be difficult to detect. The test provides objective diagnostic information that helps clinicians distinguish heart failure from other disease states with similar clinical symptoms. VIDAS NT-proBNP also can be used to assess the prognosis of patients with established heart failure or acute coronary syndrome. The unique VIDAS design makes this assay available 24 hours a day for emergency departments. For more information, visit www.biomerieux-usa.com, or call 800-682-2666.
Sandoz (Princeton, NJ) recently introduced Irinotecan Hydrochloride, a generic equivalent of Pfizer Inc?s Camptosar. Sandoz launched the product, its first injectable oncology drug, upon expiration of patent protection on Camptosar. Irinotecan Hydrochloride is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Each milliliter of Irinotecan Hydrochloride contains 20 mg irinotecan (on the basis of the trihydrate salt), 45 mg sorbitol, and 0.9 mg lactic acid. The product is available in single-dose vials in 2- and 5-mL packages. For more information, visit www.us.sandoz.com.
Find it Online
For more Hospital Product News, visit www.PharmacyTimes.com/HospitalProducts